Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
Albert, albumin, challenge, Chinese, CHO, corona, culture, cultured, demand, Dr, Emalfarb, enrollment, Europe, fermentation, Ferritin, Gallery, Germany, gRBD, Hannover, Hengrui, Jiangsu, Mark, meat, media, Medicine, nasal, Nivolumab, October, oncology, optimize, Ovary, pan, RNA, serum, swab, throat, underway, unmet, Veterinary, video, website
Removed:
Hazelton, reinvestment, validate
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view